Hematology, Transfusion and Cell Therapy最新文献

{"title":"ASSOCIATION BETWEEN BODY COMPOSITION AND SURVIVAL IN LOCALLY ADVANCED HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY","authors":"Larissa Ariel Oliveira Carrilho ,&nbsp;Rafaella Caroline de Lellis Moreira ,&nbsp;Fabiana Lascala Juliani ,&nbsp;Livia Dias Guerra ,&nbsp;Fernanda Silva Santos ,&nbsp;Sandra Regina Brambilla ,&nbsp;Luciana Freire de Almeida dos Anjos ,&nbsp;Davi Magalhães Leite Novaes ,&nbsp;Lígia Traldi Macedo ,&nbsp;Eduardo Baldon Pereira ,&nbsp;Carmen Silvia Passos Lima ,&nbsp;Lígia de Moraes Antunes-Correa ,&nbsp;Maria Carolina Santos Mendes ,&nbsp;José Barreto Campello Carvalheira","doi":"10.1016/j.htct.2024.04.069","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.069","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Malnutrition is a frequent condition in patients with head and neck cancer (HNC) due to the location of the tumor, treatment, and difficulty in food intake. Body composition is recognized as a prognostic factor in cancer patients, independently of nutritional status. Low muscularity (LM) is related to decreased survival in patients with HNC, however, the adipose tissue (AT) impacts in prognosis is unclear.</p></div><div><h3>Objectives</h3><p>This study evaluates the association between body composition parameters and survival in patients with locally advanced HNC.</p></div><div><h3>Materials and Methods</h3><p>A retrospective study was conducted on patients diagnosed with locally advanced HNC who received radiotherapy as the first-line treatment at the University of Campinas Hospital between January 2010 and December 2018. The total adipose tissue (TAT) area and the skeletal muscle area were measured by analyzing computed tomography (CT) images at the level of the third cervical vertebra (C3) using the SliceOMatic V. 5.0 software. The muscle cross-sectional area (CSA) at C3 was used to estimate the CSA muscle area at L3, using a specific formula.Cox proportional hazard models were used for survival analysis. Model A was adjusted for age, while model B was adjusted for age, ECOG score, diabetes, hypertension, concomitant chemotherapy, and tumor stage. Model C maintained the variables of model B plus muscularity. The statistical analysis was performed using Stata software version 17.0, and a significance level of 5% was established. The study was approved by the Research Ethics Committee of UNICAMP (CAAE: 42743120.5.0000.5404).</p></div><div><h3>Results</h3><p>Our sample included 132 patients that comprised mostly males (87.9%) aged between 55 and 70 years (60.6%) and considered eutrophic by the Body Mass Index (BMI) (52.3%). Patients in the highest tertile of TAT had a lower risk of death than those in the lowest tertile in model A [HR: 0.49 (CI 95%: 0.30–0.79); ptrend = 0.007], model B [HR: 0.56 (CI 95%: 0.32–0.96); ptrend = 0.039], and model C [HR: 0.51 (CI 95%: 0.29–0.89); ptrend = 0.017]. The highest tertile of TAT presented higher caloric intake (p = 0.030) and energy expenditure (p = 0.004). Low muscularity was associated with lower overall survival [HR = 1.77, 95%CI (1.01 - 3.07), p = 0.044)], but not with progression free survival. There was no statistical difference for NLR values between groups (p = 0.47).</p></div><div><h3>Conclusion</h3><p>Higher adiposity was a protective factor for overall survival in locally advanced HNC treated with radiotherapy. Low muscularity was associated with reduced overall survival. The assessment of body composition, added to an early nutritional intervention, and the preservation of muscle mass and adipose tissue may play a role in improving the outcomes of locally advanced HNC patients undergoing radiotherapy.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001512/pdfft?md5=2ff8fe988d236ab3f694e4f097b3eea6&pid=1-s2.0-S2531137924001512-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"177LU-PSMA IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER: PRELIMINARY ANALYSIS OF A BRAZILIAN MULTICENTRIC STUDY","authors":"Victor Cabral Costa Ribeiro Heringer ,&nbsp;Felipe P.G. Ribeiro ,&nbsp;Diogo Bastos ,&nbsp;Camila Mosci ,&nbsp;Dalton A. Anjos ,&nbsp;Paulo Almeida Filho ,&nbsp;Gustavo Gomes ,&nbsp;Filipe Villela-Pedras ,&nbsp;Fabio Ribeiro ,&nbsp;Julio Correia ,&nbsp;José F. Marin ,&nbsp;Carlos Buchpiguel ,&nbsp;Elba C.S.C. Etchebehere","doi":"10.1016/j.htct.2024.04.071","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.071","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>177Lu-PSMA can be a promissor therapy in patients with metastatic castration resistant prostate cancer.</p></div><div><h3>Objectives</h3><p>Investigate 177Lu-PSMA therapy in Brazilian patients with metastatic castration resistant prostate cancer (mCRPC).</p></div><div><h3>Materials and Methods</h3><p>Data for this retrospective multicentric study was collected from 9 Brazilian centers from 6 federative units (SP, PE, CE, RJ, SC and DF) that performed at least two cycles of 177Lu-PSMA therapy in mCRPC. Data with skewed distribution were reported as median (min-max). Primary outcome was overall survival. Secondary outcomes was the maximal PSA response and hematological adverse events (HAE).</p></div><div><h3>Results</h3><p>A total of 100 males were included, median age = 74 years old (min-max: 54 - 96 years old). 177Lu-PSMA was the fifth (median) line of therapy (min-max 2-10). A total of 333 cycles were performed with a median of 4 cycles (min-max 1-10). The mean overall survival was 12.8 months. Among the 72 patients with data available for the maximal PSA response at any time, 65% presented any PSA decline. 42% presented PSA decline ≥ 50% from baseline. 89% of patients did not present HAE or presented grades 1 or 2 HAE. Only 11% of patients presented grade 3 HAE. 0% of patients presented grade 4 HAE.</p></div><div><h3>Conclusion</h3><p>177Lu-PSMA therapy was effective and safe in the Brazilian population even with a median of 5th line of therapy (maximum 10th line). Overall survival and PSA decline ≥ 50% from baseline were similar to the literature data. Only 11% of patients presented grades 3 or 4 hematological adverse events.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001536/pdfft?md5=a98ea7937472c7e6ac04f80a96888cb2&pid=1-s2.0-S2531137924001536-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BODY COMPOSITION AND INSULIN SENSITIVITY IN PATIENTS WITH RECTAL CANCER","authors":"Maria Carolina Santos Mendes ,&nbsp;Fabiana Lascala Juliani ,&nbsp;Sandra Regina Branbilla ,&nbsp;Aglecio Luiz Souza ,&nbsp;Sarah Monte Alegre ,&nbsp;Felipe Osorio Costa ,&nbsp;Carlos Augusto Real Martinez ,&nbsp;Jose Barreto Campello Carvalheira","doi":"10.1016/j.htct.2024.04.057","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.057","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Glucose intolerance is a metabolic abnormality recognized in patients with cancer cachexia and has been implicated in the development of low muscularity (LM). LM is an important feature associated with the poor prognosis of cancer patients, leading to a reduction in functional capacity, poor quality of life, increased treatment intolerance, and reduced overall survival. LM have been shown to correlate with insulin sensitivity. However, clinical studies evaluating the association between body composition features and insulin resistance are scarce, and the results are contradictory.</p></div><div><h3>Objectives</h3><p>The purpose of this study was to evaluate the association between insulin sensitivity and the body composition features of patients recently diagnosed with rectal cancer.</p></div><div><h3>Materials and Methods</h3><p>This is a cross-sectional study involving patients diagnosed with rectal cancer. Body composition was analyzed using computed tomography (CT) images processed with the SliceOmatic software based on the difference in tissue measurements by Hounsfield Units (HU). Muscularity was categorized according to Martin's criteria. Cachexia was categorized according to Fearon's criteria. Insulin sensitivity was evaluated using euglycemic hyperinsulinemic clamp. Personal information, tumor characteristics, and biochemical exams were collected from medical records. Statistical analyses were conducted using Stata Corp LP® version 17.0 software. This study was approved by the Institutional Review Board (CAAE: 91217418.2.0000.5404).</p></div><div><h3>Results</h3><p>A total of 33 patients were included in the analysis. Low muscularity and cachexia diagnosis were identified in 27% of the sample (n = 9). The low muscularity (LM) group consisted mostly of females aged 55–70 years. There was no difference in BMI, weight loss, tumor stage, or ECOG score between muscularity groups. The LM group had a lower skeletal muscle area (p &lt; 0.001), lower visceral adipose tissue area (p = 0.01), and there is no difference in skeletal muscle radiodensity (p = 0.85), subcutaneous adipose tissue area (p = 0.76), and intramuscular adipose tissue area (p = 0.46) when compared to normal muscularity group. A lower handgrip strength was also observed in the LM group (p &lt; 0.01). Regarding insulin sensitivity, the LM group had a higher M-value adjusted for Free Fat Mass (FFM) (p = 0.01) and M-value adjusted for Total Body Weight (TBW) (p = 0.0347). Additionally, a significant negative correlation was found between muscularity and M-value-FFM (rho = -0.5047, p = 0.004) and M-value-TBW (rho = -0.4742, p = 0.0076). There was no difference in M-value between cachexia and non-cachexia patients. No statistical difference was observed in inflammatory markers (C-reactive protein, Glasgow prognostic score (mGPS), and neutrophil-to-lymphocyte ratio (NLR)) according to muscularity groups.</p></div><div><h3>Conclusion</h3><p>Th","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001391/pdfft?md5=b8e0bbaf9ec11a7e3d1921c5ab1a661c&pid=1-s2.0-S2531137924001391-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CONTRIBUIÇÃO DO PET-CT COM FDG-18F EM CASO COMPLEXO DE COEXISTÊNCIA DE LINFOMA E AMILOIDOSE","authors":"Gustavo Gomes ,&nbsp;Marian Beatrice Lourenço Martins ,&nbsp;Andresa Lima Melo ,&nbsp;Eria Fernandes Vila Almeida ,&nbsp;Gabriela El Haje Lobo ,&nbsp;Ana Carolina Rezende Freitas Cravo ,&nbsp;Janaina França Magalhães Souto ,&nbsp;Marcelo Vale Gomes","doi":"10.1016/j.htct.2024.04.105","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.105","url":null,"abstract":"<div><h3>Introdução/Justificativa</h3><p>O PET-CT com FDG-18F é amplamente empregado no estadiamento inicial e avaliação de resposta terapêutica nas doenças linfoproliferativas, bem como na suspeita de recidiva. No entanto, seus achados não são específicos, já que a glicose radiomarcada identifica sítios com aumento da atividade metabólica, observados em diversas neoplasias malignas, bem como em processos inflamatórios ou infecciosos.</p></div><div><h3>Relato</h3><p>Feminino, 73 anos, tratada em 2021 para linfoma linfoplasmacítico indolente, com boa resposta. Evoluiu com sintomas respiratórios recorrentes, atribuídos a processos infecciosos de repetição, apesar da terapêutica antimicrobiana prolongada. Desenvolveu manifestações orotraqueais importantes, cursando com insuficiência respiratória, resultando em traqueostomia. Propedêutica evidenciou amiloidose, sendo instituído tratamento específico, com resposta clínica favorável. Na reavaliação com médico assistente, a paciente apresentava tosse e dispneia, sendo submetida a TC de tórax que evidenciou adenomegalias mediastinais. Diante da suspeita clínica de recidiva do linfoma, solicitou-se PET-CT com FDG-18F para elucidação e definição de conduta, que mostrou aumento volumétrico e hipermetabólico das glândulas salivares maiores, consolidações pulmonares paracardíacas bilaterais acentuadamente hipermetabólicas associadas a redução volumétrica dos lobos médio e inferior esquerdo, além de linfonodos cervicais, axilares e mediastinais discretamente hipermetabólicos. Os achados do PET-CT levaram a suspeita da coexistência de: amiloidose em atividade, sobretudo no parênquima pulmonar e possivelmente nas glândulas salivares; e recidiva do linfoma nas cadeias linfonodais alteradas. Sugeriu-se, então, estudo anatomopatológico das áreas hipermetabólicas que mostrou: 1. deposição amiloide no interstício e paredes dos vasos pulmonares, fibrose estromal e infiltrado linfocítico intersticial e algo nodular de linfócitos pequenos e heterogêneos; ausência de evidências de doença linfoproliferativa; 2. doença linfoproliferativa B de pequenas células, associada a presença de acúmulos de material amiloide no interstício e paredes dos vasos na glândula submandibular esquerda e nos linfonodos cervicais ipsilaterais, consistente com linfoma da zona marginal, com acúmulo secundário amiloide.</p></div><div><h3>Conclusão</h3><p>O PET-FDG tem papel bem estabelecido nas doenças linfoproliferativas, desde o diagnóstico inicial e avaliação de resposta, bem como na recidiva, podendo definir, em exame único, a extensão da doença, características metabólicas, além de sugerir sítio de biópsia. Na amiloidose este método tem sua importância, demonstrando atividade e extensão da doença. Diante da coexistência das entidades, o PET-FDG pode então definir a conduta terapêutica inicial. Comentários Finais: O caso apresentado demonstra a contribuição do PET-FDG na coexistência de doenças sistêmicas, ao indicar sítios de biópsia, demonst","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001871/pdfft?md5=b814f6fe263997ac9407dcb7eaf29099&pid=1-s2.0-S2531137924001871-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F- FDG PET/CT IN MELANOMA OF PROBABLE ANORECTAL ORIGIN: CASE REPORT","authors":"Felipe Piccarone Gonçalves Ribeiro ,&nbsp;Thiago Ferreira de Souza ,&nbsp;Dihego Ferreira dos Santos ,&nbsp;Allan de Oliveira Santos ,&nbsp;Mariana da Cunha Lopes de Lima ,&nbsp;Elba Cristina Sá de Camargo Etchebehere ,&nbsp;Celso Darío Ramos ,&nbsp;Bárbara Juarez Amorim","doi":"10.1016/j.htct.2024.04.106","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.106","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Anorectal melanoma is a rare tumor that develops in melanin producing pigment cells of the anus and rectum. As a rare entity there is not much literature regarding the management of this pathology. It`s a difficult diagnosis and the majority of patients present metastases. Therefore we presented a case of probable anorectal melanoma submitted to 18F-FDG PET/CT.</p></div><div><h3>Report</h3><p>76 years old, male with history of anal pain and sporadic bleeding after bowel movement in the last 6 months. Bowel habits of 3-4 times daily and weight loss not quantified in the period. Digital rectal examination revealed a vegetative, friable and painful lesion, found 1 cm from anal verge, in the anterior wall, extending for 3 cm and presence of blood. Colonoscopy revealed an infiltrative, multilobular, friable and non stenosing lesion, measuring 5 cm and including pectineal line and anterior wall of the anus. Biopsy revealed colorectal mucosa with atypical cellular proliferation and ulceration and immunohistochemistry demonstrated markers that confirmed the diagnosis of melanoma (primary lesion or metastatic). Chest and abdominal CT scans demonstrated lung, liver and left adrenal lesions. 18F- FDG PET/CT was performed for primary staging. PET scan revealed hypermetabolism in anorectal wall thickening, that might be the primary lesion and in multiple hypermetabolic lesions in thyroid, lungs, liver, left adrenal, stomach lesser curvature, retroperitoneal and pelvic nodes, peritoneal implants and bones, suggesting metastatic involvement.</p></div><div><h3>Conclusion</h3><p>This report shows a patient with a clinical picture, physical examination and complementary exams compatible with anorectal neoplasia. Immunohistochemistry confirms the diagnosis of melanoma. Anorectal melanomas are extremely rare and aggressive. Lymphatic dissemination of anal melanomas results in distant metastases to the liver and lungs by up to 90% of cases. These findings are in line with the FDG PET/CT reported in our study. 18F-FDG PET/CT may be useful in the primary staging of anal melanoma patients and in identifying lesions missed by other conventional radiological methods.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001883/pdfft?md5=2c1fd6ed6686160d71d8ed7586fe930b&pid=1-s2.0-S2531137924001883-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AUTOMATED SYNTHESIS AND IN VITRO STUDIES OF [68GA]GA-FAPI-46 IN HOSPITAL RADIOPHARMACY","authors":"Leonardo Lima Fuscaldi ,&nbsp;Paloma Caiado Lupinari ,&nbsp;Karen Alessandra Kazumi Sato ,&nbsp;Ana Claudia Camargo Miranda ,&nbsp;Solange Nogueira Amorim ,&nbsp;Taise Vitor ,&nbsp;Jairo Wagner ,&nbsp;Vasko Kramer ,&nbsp;Lilian Yuri Itaya Yamaga ,&nbsp;Luciana Malavolta ,&nbsp;Marycel Figols de Barboza","doi":"10.1016/j.htct.2024.04.059","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.059","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Early evidence appointed fibroblast activation protein (FAP), a type II transmembrane serine protease, as highly expressed in the stroma of various tumor entities, designating FAP as the next target for cancer studies in nuclear medicine. Several radiolabeled fibroblast activation protein inhibitors (FAPI) are currently in development and investigation as potential PET imaging agents for different neoplasms, with the potential for future theranostic applications.</p></div><div><h3>Objectives</h3><p>The aim of this study was to implement the efficient and convenient automated synthesis of [68Ga]Ga-FAPI-46 from ABX, using Modular Lab Pharm Tracer and the generator Gallia Pharm® from Eckert &amp; Ziegler, for clinical applications in nuclear medicine services, as well as to evaluate routine quality control parameters such as radiochemical yield and purity, radiochemical stability, and sterility tests in accordance with the GMP rules.</p></div><div><h3>Materials and Methods</h3><p>The synthesis was conducted in automated module, employing disposable cassettes in an adapted synthesis template with high purity raw materials and reagents. [68Ga]GaCl3 was percolated through resin and eluted with 0.5 mL of 5.5 M HCl in saline into a reaction vial containing 50 μg of FAPI-46 in 1.5 mL of 0.1 M acetate buffer (pH = 4.5) and 100 µL of ethanol. The solution was heated at 95°C for 10 min. The resulting product was purified through a Sep-Pak C18 cartridge, which was pre-conditioned with ethanol and 0.9% saline, and eluted with 0.4 mL of 70% ethanol. The final product was diluted with 0.9% saline and filtered through a Millipore 0.22 µm filter. Radiochemical yield (RCY) was assessed by determining the activity retained in the module in relation to the final product. Radiochemical purity (RCP) of [68Ga]Ga-FAPI-46 was analyzed by ascending chromatography using either ITLC-SG strip and 0.1 M ammonium acetate and methanol (1:1) solution or TLC and 1 M sodium citrate (pH = 5.5), and Sep-Pak C18 cartridge. Radiochemical stability was assessed through UHPLC analysis. Microbiological, pyrogenic, and filter tests were conducted on all batches. Additionally, in-vitro studies were carried out to assess Log P and serum protein binding for [68Ga]Ga-FAPI-46.</p></div><div><h3>Results</h3><p>The automated synthesis produced [68Ga]Ga-FAPI-46 with an activity of 684 ± 67 MBq, a RCY of 88.4 ± 2.6%, and pH = 4.5 (n = 8). The RCP was determined as 97.32 ± 1.92% by ascending chromatography and 97.74 ± 2.12% by Sep-Pak C18 cartridge. The RCP remained above 97% for more than 120 min as analyzed by UHPLC, showing high radiochemical stability. Microbiological assays demonstrated that the final product was obtained as a sterile and pyrogen free solution. The filter test passed for all batches. The Log P was determined as -3.57 ± 0.15 (n = 10), showing the hydrophilic characteristics of [68Ga]Ga-FAPI-46 with a serum protein binding of 52.11 ± 1.4","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S253113792400141X/pdfft?md5=2653686572c5378ae3fd0f8a9c711892&pid=1-s2.0-S253113792400141X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68GA-NOTA-UBI AND 68GA-DOTA-UBI AS RADIOPHARMACEUTICALS FOR THE DIAGNOSIS OF INFECTIOUS PROCESSES: PRECLINICAL STUDIES AND TRANSLATION TO CLINICAL APPLICATION","authors":"Ana Claudia Camargo Miranda ,&nbsp;Caiubi Rodrigues de Paula Santos ,&nbsp;Leonardo Lima Fuscaldi ,&nbsp;Fernanda Ferreira Mendonça ,&nbsp;Solange Amorim Nogueira ,&nbsp;Jorge Mejia ,&nbsp;Akemi Osawa ,&nbsp;Lilian Yuri Itaya Yamaga ,&nbsp;Marycel Figols de Barboza ,&nbsp;Luciana Malavolta","doi":"10.1016/j.htct.2024.04.052","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.052","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Infectious diseases are the second leading cause of mortality worldwide. In this context, considerable efforts are being made to develop radiopharmaceuticals that enable the accurate diagnosis of bacterial infections. A new field of research is focusing on antimicrobial peptides, such as Ubiquicidin. The 29-41 fragment (Thr-Gly-Arg-Ala-Lys-Arg-Arg-Met-Gln-Tyr-Asn-Arg-Arg) UBI(29-41) labeled with radionuclides has proved to be an important tool for the specific diagnosis of infectious processes.</p></div><div><h3>Objectives</h3><p>To present the radiochemical and \"in vitro\" studies of UBI(29-41) with the chelating agents 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for labeling with gallium-68 (68Ga) and to validate with a clinical application.</p></div><div><h3>Materials and Methods</h3><p>After 68GaCl3 elution, the NOTA-UBI and DOTA-UBI reactions were performed at 85oC for 5 min and 95oC for 15 min, respectively. In both cases, the purification was carried out using a Sep-Pak C18 filter and radiochemical control by Thin-Layer Chromatography (TLC) and High-Performance Liquid Chromatography (HPLC). The partition coefficient (Log P) and serum protein binding were determined, as well as the stability in saline and serum up to 90 min. After these studies, assays were carried out to determine the binding of the radiopharmaceuticals to \"Staphylococcus aureus\" bacteria. For the clinical study, the patient selected had a diagnosis of chronic osteomyelitis in the distal tibia, a positive blood culture for \"Staphylococcus aureus\" and a possible infectious/inflammatory process at the site identified by magnetic resonance imaging. The patient was injected intravenously with 281 MBq of 68Ga-DOTA-UBI to confirm the presence of an infectious process by PET-CT and the images were obtained 1 h post-administration. Resultados: The radiochemical purity (RP) of the radiopharmaceuticals after purification was 99.28±0.28% and 99.78±0.06% for 68Ga-NOTA-UBI and 68Ga-DOTA-UBI, respectively. Log P was -3.57±0.20 for 68Ga-NOTA-UBI and -3.63±0.17 for 68Ga-DOTA-UBI. Stability studies up to 90 min showed RP of 98.13±0.78% and 99.75±0.08% in saline; and 79.94±5.10% and 94.69±1.14% in serum, for 68Ga-NOTA-UBI and 68Ga-DOTA-UBI, respectively. The percentage of serum protein binding, evaluated at 30 and 60 min, was 59.90±1.21% and 53.45±2.16% for 68Ga-NOTA-UBI and 60.22±2.96% and 44.06±1.88% for 68Ga-DOTA-UBI, respectively. The binding of radiopharmaceuticals to \"Staphylococcus aureus\" revealed a direct relation to the amount of bacteria in the culture. Clinical images showed intense uptake of the radiopharmaceutical in the entire remnant of the talus and in the adjacent soft tissues of the left ankle. After scan, the secretion collected from the surgical site was cultured and the presence of \"Staphylococcus aureus\" was confirmed.</p></div><div><h3>Conclusion</h3","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001342/pdfft?md5=39f658a2d2206c333ae3fca620178987&pid=1-s2.0-S2531137924001342-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMPARISON OF IBI AND PBI CALCULATED FOR 68GA-PSMA AND 18F-FDG IN MULTIPLE MYELOMA PATIENTS","authors":"Maria Emilia Seren Takahashi ,&nbsp;Stephan P.M. Souza ,&nbsp;Fernanda C. Frasson ,&nbsp;Gislaine B. Oliveira ,&nbsp;Vania P. Castro ,&nbsp;Fernando V. Pericole ,&nbsp;Lício A. Velloso ,&nbsp;Cármino A. Souza ,&nbsp;Irene G.H. Lorand-Metze ,&nbsp;Allan O. Santos ,&nbsp;Celso Darío Ramos","doi":"10.1016/j.htct.2024.04.087","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.087","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>The benefits of using 18F-FDG PET/CT for staging and managing treatment in patients with multiple myeloma (MM) are extensively documented. Recent studies indicate that 68Ga-PSMA PET/CT is also an excellent marker for MM lesions and may complement 18F-FDG due to the significant genetic heterogeneity observed in these patients' lesions. The involvement of bone tissue stands out as one of the most critical aspects of MM. To quantify this involvement, two quantitative parameters have recently been proposed: Percentage of Bone Involvement (PBI) and Intensity of Bone Involvement (IBI).</p></div><div><h3>Objectives</h3><p>This study aims to compare PBI and IBI in 68Ga-PSMA and 18F-FDG PET/CT images for multiple myeloma patients.</p></div><div><h3>Materials and Methods</h3><p>Fifteen patients were included in the study, 8 men (53.3%), with a mean age of 66.7 ± 10.7 years. The patients underwent 68Ga-PSMA and 18F-FDG PET/CT scans with a maximum interval of 8 days between images (median 4 days). The bone tissue was segmented in the images based on the Hounsfield scale of the CT image, followed by processing for closing of the volume of interest (VOI). Both PBI and IBI were calculated for the two radiotracers, with the liver SUV used as a reference for 18F-FDG and the left atrium as a reference for 68Ga-PSMA. Spearman's rank-order correlation assessed the relationship between PBI and IBI data.</p></div><div><h3>Results</h3><p>On average, PBI values were higher for 68Ga-PSMA than for FDG, at 3.07% ± 2.5% and 1.96% ± 3.8%, respectively. The mean IBI values were similar for both radiotracers: 0.08 ± 0.13 for 18F-FDG and 0.08 ± 0.09 for 68Ga-PSMA. The median IBI calculated for 68Ga-PSMA was 0.05, higher than the 0.01 found for 18F-FDG. Despite the similarity in average values between 68Ga-PSMA and 18F-FDG, the maximum PBI and IBI values were found in different patients for both radiotracers. Additionally, the Spearman test did not indicate correlation between the variables: (r = 0.39; p = 0.16) for PBI and (r = 0.41; p = 0.13) for IBI.</p></div><div><h3>Conclusion</h3><p>The average and maximum values of PBI and IBI for 68Ga-PSMA and 18F-FDG are close. However, no correlation was found between them, highlighting that the heterogeneous genetic profile of the disease results in different uptake patterns for both radiotracers.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S253113792400169X/pdfft?md5=851d12fb7071ea838d867ad3d0ca231d&pid=1-s2.0-S253113792400169X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FLUORIDE PET/CT vs 18F-PSMA-1007 TO DETECT BONE METASTASES IN PROSTATE CANCER – A HEAD-TO-HEAD PROSPECTIVE COMPARISON","authors":"Beatriz Birelli do Nascimento ,&nbsp;Allan Santos ,&nbsp;Natalia Tobar ,&nbsp;Fabiana Mori ,&nbsp;Mariana Camacho ,&nbsp;Mariana Lima ,&nbsp;Edna Brunetto ,&nbsp;Sergio Brunetto ,&nbsp;Anelise Ruzzarin ,&nbsp;Juliana Ciampi ,&nbsp;Marina Silveira ,&nbsp;Gardenia Oliveira Barbosa ,&nbsp;Wagner Matheus ,&nbsp;Ubirajara Ferreira ,&nbsp;Elba Etchebehere","doi":"10.1016/j.htct.2024.04.088","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.088","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>There have been no head-to-head prospective studies comparing the ability of 18F-Fluoride PET/CT and 18F-PSMA-1007 PET/CT to detect bone metastases due to prostate cancer. So, this study aims to investigate the capacity of 18F-PSMA-1007 to detect bone metastases compared to the reference standard (18F-Fluoride PET/CT) in PCa patients, considering mainly the presence or absence, number and biodistribution of lesions.</p></div><div><h3>Objectives</h3><p>This prospective study aimed to compare the ability of 18F-PSMA-1007 PET/CT and 18F-Fluoride PET/CT to detect bone metastases.</p></div><div><h3>Materials and Methods</h3><p>Twenty-eight patients with prostate cancer biochemical recurrence were submitted to both 18F-PSMA-1007 PET/CT and 18F-fluoride PET/CT studies. These two radiotracers evaluated the presence or absence, number of lesions, body and bone localization, lesion pattern, and probability of malignancy.</p></div><div><h3>Results</h3><p>Twenty-eight patients with prostate cancer biochemical recurrence, mean age of 70.8 ± 8.7 years; Gleason score = 7.72 ± 1.23 and the mean total PSA = 50.2 ± 183.9 ng/mL were included. On a per-patient basis, considering that 18F-Fluoride PET/CT is the gold standard, the 18F-PSMA-1007 PET/CT presented a concordance rate of 96.43%, sensitivity (S) of 92.3%, specificity (E) of 100%, predictive positive value (PPV) of 100% and predictive negative value (PNV) of 93.80% on lesion detection. Evaluating the number of lesions, 18F-PSMA-1007 PET/CT determined a PPV of 91.8% and sensitivity of 86.5%. Bone localization in 18F- Fluoride and 18F-PSMA-1007 were predominant in the dorsal spine (34.62%/62.65%), ribs (32.69%/32.65%)and pelvis (9.62%/12.24%), respectively. Both studies had a concordant rate of 80.76% on rib evaluation, the most conflicting site of uptake between the methods in actual literature.</p></div><div><h3>Conclusion</h3><p>18F-PSMA-1007 has the same ability as 18F-Fluoride to detect PCa bone metastasis in biochemical recurrence, with concordance of 96,43% and 80,00% on a per-patient and per-lesion evaluation, respectively. Both studies demonstrated predominancy of sclerotic and medullar lesions, located preferentially on dorsal spine and ribs, being the last one concordant in 80,76% of studies.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001706/pdfft?md5=91d3debf5c461e682548c96cbd9ac5bc&pid=1-s2.0-S2531137924001706-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN MUSCULOSKELETAL TUMORS TO EVALUATE THE POTENTIAL OF THERANOSTICS APPROACH","authors":"Mayara Branco E. Silva ,&nbsp;Natalia Tobar ,&nbsp;Allan de Oliveira Santos ,&nbsp;Gardenia De Oliveira Barbosa ,&nbsp;Carlos Eduardo Hideo Hanasilo ,&nbsp;Mariana Da Cunha Lopes de Lima ,&nbsp;Mauricio Etchebehere ,&nbsp;Elba Cristina Sa de Camargo Etchebehere","doi":"10.1016/j.htct.2024.04.089","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.089","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Sarcomas are malignant tumors in the bone, cartilage, fat, muscles, and vessels. Sar- comas are highly heterogeneous due to the wide variety of histological subtypes and various ana- tomical locations, and thus, the diagnosis and management of these tumors are challenging. Beyond sarcomas, the musculoskeletal system is a frequent site of metastatic tumors and multiple myeloma with lesions that present difficult local control. Imaging exams such as MRI and 18F-FDG (FDG PET/CT) to assess the extent of these tumors play a crucial role in managing these patients. How- ever, PET/CT imaging with 18F-PSMA-1007 (PSMA PET/CT) may be a more interesting diagnostic marker due to the potential Theranostics implications.</p></div><div><h3>Objectives</h3><p>This study aimed to compare the performance of FDG PET/CT and PSMA PET/CT images in patients with advanced-stage unresectable recurrent and metastatic musculoskeletal tumors.</p></div><div><h3>Materials and Methods</h3><p>Patients underwent FDG PET/CT and PSMA PET/CT imaging with a 24-hour interval be- tween studies. Two nuclear medicine physicians compared imaging findings.</p></div><div><h3>Results</h3><p>Eight patients underwent FDG PET/CT and PSMA PET/CT images. In five patients, PSMA uptake was higher than FDG uptake. The highest PSMA uptake occurred in a giant cell recurrent sacral tumor of a 27-year-old male patient; the SUVs for PSMA and FDG were 100 and 16, respec- tively. A 58-year-old male patient with osteolytic metastasis from renal cell carcinoma in the right scapula presented PSMA uptake higher than FDG (SUVs = 40 and 11, respectively). A recurrent spin- dle cell neural tumor in the upper limb of a 69-year-old male presented PSMA uptake also higher than FDG (SUVs = 27 and 8, respectively). A myxofibrosarcoma mass in the distal right leg of a 61- year-old female presented higher PSMA uptake slightly higher than FDG uptake (SUVs = 18 and 10, respectively). Interestingly, two patients with chordomas had heterogeneous PSMA and FDG up- take. The PSMA PET/CT of a 65-year-old male patient presenting multiple metastases from chor- doma with soft tissue invasion showed uptake higher than FDG in all lesions; the highest SUV was a lesion in the right acetabulum: PSMA SUV = 32 and FDG SUV = 19. This patient presented PSMA-avid additional sites of metastases in mediastinal lymph nodes and the right hepatic lobe, while FDG uptake was minimal in these metastases. In contrast, an FDG PET/CT of a 54-year-old male with a large recurrent chordoma (30x24 cm mass) extending from the level of L4 to the proximal left thigh presented FDG uptake higher than PSMA uptake (SUVs = 31 and 9, respectively). Also, FDG uptake of two patients (52-year-old males) with desmoid tumors in the upper limb was higher than PSMA uptake, although uptake of both radiotracers was low: PSMA SUVs of 3 and 5, and FDG SUVs of 4 and 7.</p></div><div><h3>Conclusion</h3><p>The study results show the pot","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001718/pdfft?md5=c2d916ff071dbe6b49fb43bc89aab49b&pid=1-s2.0-S2531137924001718-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140902402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}